Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer Stage 0
Currently, there are 2 ongoing clinical trials focused on early-stage lung cancer. These studies are taking place in several European countries and are testing new diagnostic methods and treatment combinations to improve outcomes for patients with lung cancer at various stages.
Clinical trial locations
- Czechia
- Germany
- Hungary
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is examining a combination treatment approach for a specific type of lung cancer called large-cell neuroendocrine carcinoma. The study is taking place in Germany and focuses on testing how well immunotherapy works together with standard chemotherapy drugs.
Main inclusion criteria: To participate, you must be at least 18 years old with a confirmed diagnosis of locally advanced or metastatic large-cell neuroendocrine carcinoma that cannot be cured with surgery. You should not have received previous treatment that affects the entire body, or if you did receive such treatment, your cancer must have returned at least 6 months after treatment ended. You need to have a performance status score between 0 and 2, meaning you can perform most daily activities. Your organs must be functioning adequately, with liver and kidney tests within acceptable ranges, and you need to have measurable disease that can be tracked with imaging scans.
Main exclusion criteria: You cannot participate if you have received any cancer treatment in the past 4 weeks, have severe allergies to the study drugs, or have active infections requiring treatment. Pregnant or breastfeeding women are not eligible. If you have participated in another clinical trial within the last 4 weeks, have had another type of cancer in the past 5 years (unless it has been in complete remission), or have untreated brain metastases, you will not be able to join. People with autoimmune diseases or a recent history of drug or alcohol abuse within the past year are also excluded.
Focus and goals: The trial aims to evaluate how effective the combination of Atezolizumab with platinum-based chemotherapy (Carboplatin or Cisplatin) and Etoposide is in improving survival rates for patients with this aggressive form of lung cancer. Researchers will monitor how the cancer responds to treatment, including changes in tumor size and the time it takes for the cancer to start growing again. The study will also carefully track any side effects participants experience to understand the safety profile of this treatment combination.
Investigational drugs: The main investigational drug is Atezolizumab, an immunotherapy medication that helps your immune system recognize and attack cancer cells. It works by blocking a protein that normally helps cancer cells hide from the immune system. This drug is being tested alongside standard chemotherapy drugs including Platinum-based drugs (Carboplatin or Cisplatin), which damage cancer cell DNA to stop them from growing, and Etoposide, which interferes with DNA inside cancer cells to prevent them from dividing. All medications are given through intravenous infusion directly into your bloodstream.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is testing a new diagnostic approach called the OWL-EVO1 Breath Biopsy test. The study is being conducted in Hungary and Czechia and represents an innovative way to detect lung cancer through breath analysis rather than invasive procedures.
Main inclusion criteria: You can participate if you are between 45 and 85 years old and can understand the study requirements well enough to provide informed consent. Your Body Mass Index (BMI) needs to be between 16 and less than 40. You must have had a CT scan that includes your chest area within the past 6 months. This scan could be part of routine lung cancer screening or because something suspicious was found that needs further investigation.
Main exclusion criteria: You cannot join if you are not eligible for lung cancer screening based on standard low-dose CT scan criteria. If your CT scan shows no suspicious findings that could indicate lung cancer, or if lung cancer is not being considered as a possible diagnosis for your symptoms, you will not be eligible for this study.
Focus and goals: The main purpose of this trial is to determine how accurately the OWL-EVO1 Breath Biopsy test can identify lung cancer in people who are either undergoing screening or have suspicious findings on their CT scans. The test works by analyzing breath samples to detect specific markers that may indicate cancer presence. Researchers will compare the test results with actual diagnoses to see how well it performs in distinguishing between people with lung cancer and those with other conditions that might look similar on scans. The study will also evaluate whether the test is safe and well-tolerated by participants.
Investigational approach: The diagnostic tool being tested is OWL-EVO1, which involves administering a special solution called D5-ethyl-beta-D-glucuronide through an intravenous infusion. After receiving this solution, breath samples are collected at various time points. The test analyzes volatile organic compounds in your breath that can indicate the presence of cancer. This approach is designed to be non-invasive and easier for patients compared to traditional biopsy methods. The test aims to improve early detection and diagnostic accuracy for lung cancer.
Summary
The two ongoing clinical trials represent different approaches to addressing lung cancer challenges. One trial focuses on treatment, testing a combination of immunotherapy and chemotherapy for advanced disease in Germany. The other takes a diagnostic approach, evaluating a novel breath-based test for cancer detection in Hungary and Czechia.
Geographically, these studies are concentrated in Central Europe, with the diagnostic trial spanning multiple countries. The treatment trial uses Atezolizumab as the key investigational immunotherapy drug, while the diagnostic trial employs an innovative breath analysis technology. Both studies address important needs in lung cancer care: improving treatment outcomes for advanced disease and enhancing early detection methods. Patients interested in participating should discuss eligibility with their healthcare providers, as the trials have specific requirements regarding disease stage, prior treatments, and overall health status.
